The second exclusive vaccine technology licensing deal with The Pirbright Institute (a leading UK-based veterinary research body), announced this morning, targets the prevention of four poultry diseases of significant economic importance, and adds to ECO’s already exciting portfolio of development-stage vaccines. We look forward to further development updates with interest, and reiterate our positive stance.
11 Sep 2019
Further vaccine pipeline expansion: 2nd deal with The Pirbright Institute
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further vaccine pipeline expansion: 2nd deal with The Pirbright Institute
ECO Animal Health Group plc (EAH:LON) | 94.0 0 0.0% | Mkt Cap: 63.7m
- Published:
11 Sep 2019 -
Author:
Jens Lindqvist -
Pages:
3
The second exclusive vaccine technology licensing deal with The Pirbright Institute (a leading UK-based veterinary research body), announced this morning, targets the prevention of four poultry diseases of significant economic importance, and adds to ECO’s already exciting portfolio of development-stage vaccines. We look forward to further development updates with interest, and reiterate our positive stance.